BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38738190)

  • 1. Author Response.
    Vijayakumar M; Selvam V; Renuka MK; Rajagopalan RE
    Indian J Crit Care Med; 2024 May; 28(5):515. PubMed ID: 38738190
    [No Abstract]   [Full Text] [Related]  

  • 2. Author Response.
    Vijayakumar M; Selvam V; Renuka MK; Rajagopalan RE
    Indian J Crit Care Med; 2024 May; 28(5):512. PubMed ID: 38738204
    [No Abstract]   [Full Text] [Related]  

  • 3. The Comparative Efficacy of Ceftazidime-Avibactam with or without Aztreonam vs Polymyxins for Carbapenem-resistant Enterobacteriaceae Infections: A Prospective Observational Cohort Study.
    Vijayakumar M; Selvam V; Renuka MK; Rajagopalan RE
    Indian J Crit Care Med; 2023 Dec; 27(12):923-929. PubMed ID: 38074953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Clinically Significant Bleeding in Thrombocytopenic Dengue Patients Admitted to Intensive Care Unit: A Retrospective Study.
    Logia P; Selvam V; Parasuraman V; Renuka MK; Rajagopalan RE
    Indian J Crit Care Med; 2023 Dec; 27(12):888-894. PubMed ID: 38074960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis.
    Prayag PS; Patwardhan SA; Panchakshari S; Sambasivam R; Dhupad S; Soman RN; Prayag AP
    Indian J Crit Care Med; 2023 Jun; 27(6):444-450. PubMed ID: 37378372
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcome of Patients on Ceftazidime-Avibactam and Combination Therapy in Carbapenem-resistant Enterobacteriaceae.
    Nagvekar V; Shah A; Unadkat VP; Chavan A; Kohli R; Hodgar S; Ashpalia A; Patil N; Kamble R
    Indian J Crit Care Med; 2021 Jul; 25(7):780-784. PubMed ID: 34316172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study.
    Zheng G; Zhang J; Wang B; Cai J; Wang L; Hou K; Zhang Y; Zhang L; Yang Z; He J; Bian X
    Infect Dis Ther; 2021 Sep; 10(3):1699-1713. PubMed ID: 34241831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing
    Isler B; Ezure Y; Romero JLG; Harris P; Stewart AG; Paterson DL
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of
    Han R; Shen S; Yin D; Ding L; Shi Q; Yang Y; Guo Y; Wu S; Zhi P; Zhu D; Hu F
    Microbiol Spectr; 2023 Feb; 11(2):e0272022. PubMed ID: 36744897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study.
    Meng H; Zhao Y; An Q; Zhu B; Cao Z; Lu J
    Infect Drug Resist; 2023; 16():5815-5824. PubMed ID: 37692471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Author Response to the Letter to Editor "Reckoning the Inhaled Sedation in Critically Ill Patients: INSTINCT I".
    Kulkarni AP; Bhosale SJ
    Indian J Crit Care Med; 2022 Nov; 26(11):1229. PubMed ID: 36873592
    [No Abstract]   [Full Text] [Related]  

  • 13. Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and
    Zalas-Więcek P; Prażyńska M; Pojnar Ł; Pałka A; Żabicka D; Orczykowska-Kotyna M; Polak A; Możejko-Pastewka B; Głowacka EA; Pieniążek I; Pawlik M; Grys M; Bogiel M
    Infect Drug Resist; 2022; 15():1289-1304. PubMed ID: 35370409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant
    Vena A; Giacobbe DR; Castaldo N; Cattelan A; Mussini C; Luzzati R; Rosa FG; Del Puente F; Mastroianni CM; Cascio A; Carbonara S; Capone A; Boni S; Sepulcri C; Meschiari M; Raumer F; Oliva A; Corcione S; Bassetti M
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32050434
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against
    Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
    Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
    Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia.
    Gatti M; Pascale R; Cojutti PG; Rinaldi M; Ambretti S; Conti M; Tedeschi S; Giannella M; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Jan; 61(1):106699. PubMed ID: 36464151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].
    Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A
    Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.